share_log

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Novo-Nordisk A/S | 6-K: Novo Nordisk A/S - Share Repurchase Programme

Novo Nordisk A/S-股票回购计划
美股sec公告 ·  04/17 06:10
Moomoo AI 已提取核心信息
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program initiated on February 6, 2024. As part of a larger 12-month buyback plan worth up to DKK 20 billion, the company has been actively purchasing B shares. From February 6 to April 30, 2024, Novo Nordisk is set to repurchase shares amounting to DKK 2.1 billion. Recent transactions, as of April 12, 2024, show that the company has acquired 1,926,500 B shares at an average price of DKK 864.79 each, totaling DKK 1,666,024,627. These transactions have increased Novo Nordisk's treasury shares to 48,467,207 B shares, which is 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.
Novo Nordisk A/S, a leading global healthcare company, has reported progress on its share repurchase program initiated on February 6, 2024. As part of a larger 12-month buyback plan worth up to DKK 20 billion, the company has been actively purchasing B shares. From February 6 to April 30, 2024, Novo Nordisk is set to repurchase shares amounting to DKK 2.1 billion. Recent transactions, as of April 12, 2024, show that the company has acquired 1,926,500 B shares at an average price of DKK 864.79 each, totaling DKK 1,666,024,627. These transactions have increased Novo Nordisk's treasury shares to 48,467,207 B shares, which is 1.1% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange. Novo Nordisk, with a history dating back to 1923, is committed to combating serious chronic diseases and employs approximately 63,400 people worldwide.
全球领先的医疗保健公司诺和诺德A/S报告了其于2024年2月6日启动的股票回购计划的进展。作为价值高达200亿丹麦克朗的更大规模的12个月回购计划的一部分，该公司一直在积极购买B股。从2024年2月6日至4月30日，诺和诺德将回购总额为21亿丹麦克朗的股票。截至2024年4月12日，最近的交易显示，该公司已收购了1,926,500股B股，平均每股价格为864.79丹麦克朗，总额为1,666,024,627丹麦克朗。这些交易使诺和诺德的库存股增加到48,467,207亿股，占股本的1.1％。该公司的股票在哥本哈根纳斯达克和纽约证券交易所上市。诺和诺德的历史可以追溯到1923年，致力于抗击严重的慢性病，在全球拥有约63,400名员工。
全球领先的医疗保健公司诺和诺德A/S报告了其于2024年2月6日启动的股票回购计划的进展。作为价值高达200亿丹麦克朗的更大规模的12个月回购计划的一部分，该公司一直在积极购买B股。从2024年2月6日至4月30日，诺和诺德将回购总额为21亿丹麦克朗的股票。截至2024年4月12日，最近的交易显示，该公司已收购了1,926,500股B股，平均每股价格为864.79丹麦克朗，总额为1,666,024,627丹麦克朗。这些交易使诺和诺德的库存股增加到48,467,207亿股，占股本的1.1％。该公司的股票在哥本哈根纳斯达克和纽约证券交易所上市。诺和诺德的历史可以追溯到1923年，致力于抗击严重的慢性病，在全球拥有约63,400名员工。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息